Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy

Nasimul Ahsan, Michael J. Holman, Douglas A. Katz, Catherine Abendroth, Harold C. Yang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Despite the use of newer immunosuppressive drugs, early allograft rejection is still a major cause of graft loss and diminished graft survival. The pathological picture of acute interstitial rejection usually responds to high dose steroids, whereas the treatment of acute vascular (AVR) rejection characterized by an intense vasculitis and/or endotheliolitis is more formidable. The use of newer monoclonal antibodies specific for T lymphocytes and their subsets has only been occasionally successful in reversing AVR. Here we report a case of successful reversal of acute vascular renal allograft rejection with mycophenolate mofetil (MMF) and tacrolimus as primary therapy.

Original languageEnglish (US)
Pages (from-to)94-97
Number of pages4
JournalClinical Transplantation
Volume11
Issue number2
StatePublished - Apr 1 1997

Fingerprint

Mycophenolic Acid
Tacrolimus
Immunotherapy
Allografts
Blood Vessels
Kidney
T-Lymphocyte Subsets
Graft Survival
Immunosuppressive Agents
Vasculitis
Steroids
Monoclonal Antibodies
Transplants
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

@article{41570b41d67442f1b5ada857aa053d72,
title = "Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy",
abstract = "Despite the use of newer immunosuppressive drugs, early allograft rejection is still a major cause of graft loss and diminished graft survival. The pathological picture of acute interstitial rejection usually responds to high dose steroids, whereas the treatment of acute vascular (AVR) rejection characterized by an intense vasculitis and/or endotheliolitis is more formidable. The use of newer monoclonal antibodies specific for T lymphocytes and their subsets has only been occasionally successful in reversing AVR. Here we report a case of successful reversal of acute vascular renal allograft rejection with mycophenolate mofetil (MMF) and tacrolimus as primary therapy.",
author = "Nasimul Ahsan and Holman, {Michael J.} and Katz, {Douglas A.} and Catherine Abendroth and Yang, {Harold C.}",
year = "1997",
month = "4",
day = "1",
language = "English (US)",
volume = "11",
pages = "94--97",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy. / Ahsan, Nasimul; Holman, Michael J.; Katz, Douglas A.; Abendroth, Catherine; Yang, Harold C.

In: Clinical Transplantation, Vol. 11, No. 2, 01.04.1997, p. 94-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy

AU - Ahsan, Nasimul

AU - Holman, Michael J.

AU - Katz, Douglas A.

AU - Abendroth, Catherine

AU - Yang, Harold C.

PY - 1997/4/1

Y1 - 1997/4/1

N2 - Despite the use of newer immunosuppressive drugs, early allograft rejection is still a major cause of graft loss and diminished graft survival. The pathological picture of acute interstitial rejection usually responds to high dose steroids, whereas the treatment of acute vascular (AVR) rejection characterized by an intense vasculitis and/or endotheliolitis is more formidable. The use of newer monoclonal antibodies specific for T lymphocytes and their subsets has only been occasionally successful in reversing AVR. Here we report a case of successful reversal of acute vascular renal allograft rejection with mycophenolate mofetil (MMF) and tacrolimus as primary therapy.

AB - Despite the use of newer immunosuppressive drugs, early allograft rejection is still a major cause of graft loss and diminished graft survival. The pathological picture of acute interstitial rejection usually responds to high dose steroids, whereas the treatment of acute vascular (AVR) rejection characterized by an intense vasculitis and/or endotheliolitis is more formidable. The use of newer monoclonal antibodies specific for T lymphocytes and their subsets has only been occasionally successful in reversing AVR. Here we report a case of successful reversal of acute vascular renal allograft rejection with mycophenolate mofetil (MMF) and tacrolimus as primary therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030887216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030887216&partnerID=8YFLogxK

M3 - Article

C2 - 9113443

AN - SCOPUS:0030887216

VL - 11

SP - 94

EP - 97

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -